A SEROPREVALENCE STUDY OF HERPES-VIRUS TYPE-2 INFECTION IN ISRAELI WOMEN - IMPLICATIONS FOR ROUTINE SCREENING

被引:0
|
作者
ISACSOHN, M
BARON, E
YAEGER, Y
SMETANA, Z
WEINER, D
SLATER, PE
机构
[1] SHAARE ZEDEK MED CTR,MALE INFERTIL UNIT,JERUSALEM,ISRAEL
[2] SHAARE ZEDEK MED CTR,DEPT OBSTET & GYNECOL,JERUSALEM,ISRAEL
[3] HEBREW UNIV JERUSALEM,HADASSAH MED SCH,IL-91010 JERUSALEM,ISRAEL
[4] KUPAT HOLIM OUTPATIENT GYNECOL CLIN,JERUSALEM,ISRAEL
[5] MINIST HLTH,EPIDEMIOL UNIT,JERUSALEM,ISRAEL
[6] CHAIM SHEBA MED CTR,CENT VIROL LAB,IL-52621 TEL HASHOMER,ISRAEL
来源
ISRAEL JOURNAL OF MEDICAL SCIENCES | 1994年 / 30卷 / 5-6期
关键词
INFECTIOUS DISEASE; HERPES VIRUS TYPE 2; CERVICAL INFECTION; EPIDEMIOLOGY; SCREENING;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the study was to obtain data on the prevalence of herpes simples virus type 2 (HSV-2) in selected populations of women and to identify groups that might benefit from routine prenatal screening. The prospective seroprevalence study was performed in 1,921 women in Israel during the period 1986-90. Four different population groups of women 17-60 years old were included. Groups 1 and 2 comprised 1,214 healthy female government employees and kibbutz and moshav residents, and Groups 3 and 4 comprised 707 Jewish and non-Jewish women with gynecological complaints. HSV-2 antibody in the sera were studied by the microneutralization method. In the healthy women (groups 1 and 2), the prevalence of antibodies to HSV-2 was 2-3%. Genital HSV-2 asymtomatic shedding was 1%. In the women with gynecological complaints (groups 3 and 4) the prevalence of antibodies to HSV-2 was 10% in Jewish and 16% in non-Jewish women. These data support the conclusion that there is no justification for routine prenatal HSV-2 screening in Israel in a healthy female population.
引用
收藏
页码:379 / 383
页数:5
相关论文
empty
未找到相关数据